Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on American Tech Today.
Press releases published on May 12, 2025
Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million
GlobeNewswire
·
May 12, 2025
CLEVELAND, May 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 …
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
GlobeNewswire
·
May 12, 2025
Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapy Stem cell therapy laromestorcel being evaluated as potential treatment for Alzheimer’s disease and HLHS, a rare pediatric disease and orphan-designated …
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles
GlobeNewswire
·
May 12, 2025
Multiple HCPs have requested from Invivyd a monoclonal antibody (mAb) for treatment of active measles infection and post-exposure prophylaxis to reduce the consequence of outbreaks. Such a medicine could accelerate the pathway to functional eradication of …
TensorStax Raises $5M to Build Deterministic AI Agents for Data Engineers
GlobeNewswire
·
May 12, 2025
SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- TensorStax, the autonomous AI agentic platform for data engineering, today announced it has raised $5 million in Seed funding led by Glasswing Ventures, with participation from Bee Partners and S3 Ventures. …
InStride Named a 2025 World’s Top EdTech Company by TIME and Statista
GlobeNewswire
·
May 12, 2025
LOS ANGELES, May 12, 2025 (GLOBE NEWSWIRE) -- InStride, a leading provider of strategic education benefits and skills development solutions, has been recognized on the TIME World’s Top EdTech Companies 2025 list, ranking #26 globally and #7 among U.S.- …
Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights
GlobeNewswire
·
May 12, 2025
Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study LX2006 registrational study expected …
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
GlobeNewswire
·
May 12, 2025
Mike Heffernan appointed as Chairman of the Board Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Cash on hand of approximately $125 million as of March 31, 2025 expected to provide runway …
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
GlobeNewswire
·
May 12, 2025
– Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million as of March 31, 2025; cash runway …
Harvard Bioscience Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2025. Jim Green, Chairman and CEO, said, “First quarter revenues were in line …
Advantage Solutions Reports First Quarter 2025 Results
GlobeNewswire
·
May 12, 2025
Supporting clients through a challenging operating environment Continuing to make progress on transformation initiatives that will streamline operations Management lowers guidance to reflect heightened market uncertainty ST. LOUIS, May 12, 2025 (GLOBE …
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX) Presented two oral presentations and a poster presentation highlighting …
Aya Gold & Silver Secures US$25 Million Credit Facility from EBRD to Support Growth in Morocco
GlobeNewswire
·
May 12, 2025
MONTREAL, May 12, 2025 (GLOBE NEWSWIRE) -- Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to announce that it has received final internal approval by the Board of Directors of the European Bank for Reconstruction …
BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
Enrollment complete in SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support potential sNDA submission for label …
AAVantgarde presents positive clinical data from its AAVB-081 program for Usher 1B and preclinical data from its AAVB-039 program for Stargardt at the ARVO 2025 annual meeting
GlobeNewswire
·
May 12, 2025
MILAN, May 12, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces the presentation of two …
Precore Gold Announces Nomination of Louis Gariepy to Its Board of Directors, Completion of the Arikepay Agreement and Granting of Stock Options
GlobeNewswire
·
May 12, 2025
VANCOUVER, British Columbia, May 12, 2025 (GLOBE NEWSWIRE) -- Precore Gold Corp. (CSE: PRCG) (the “Company” or “Precore Gold”) is pleased to announce the nomination of Mr. Louis Gariepy, P. Eng (OIQ) for election to its Board of Directors at the Company's …
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
GlobeNewswire
·
May 12, 2025
SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced the pricing of an underwritten offering of 76,923,076 …
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4
GlobeNewswire
·
May 12, 2025
ZUG, Switzerland, May 12, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such …
Fortrea Reports First Quarter 2025 Results
GlobeNewswire
·
May 12, 2025
For the three months ended March 31, 2025, from continuing operations: Revenues of $651.3 million GAAP net loss of $(562.9) million, inclusive of a non-cash goodwill impairment charge Adjusted EBITDA of $30.3 million GAAP and adjusted net (loss) income per …
Fortrea Announces CEO Stepping Down
GlobeNewswire
·
May 12, 2025
DURHAM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that Thomas Pike is stepping down from his role as Fortrea’s Chief Executive Officer and as …
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)
GlobeNewswire
·
May 12, 2025
- 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion (7.2, 8.6 and 10 mg/kg Q3W) - - 3 of 7 evaluable patients (43%) with confirmed responses at upper expansion dose (10 mg/kg Q3W) - - Median …